Sonja Willems – Managing Director, Janssen Benelux
Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company…
Address: Archimedesstraat 11 – B1000 Brussels,Belgium
Tel: +32 2 285 42 00
Web: http://www.apb.be/Content/Default.asp
The General Pharmaceutical Association (APB) is the umbrella federation of the Belgian associations of independent pharmacists. APB represents 90 percent of the pharmaceutical corps, which essentially covers the total of the corresponding independent pharmacists.
The activities of the APB includes the advocacy of its members as well as other forms of assistance and information to its members.
Under the control of the General Assembly shall determine the general policy of the Federal Council, which is followed by the Management Committee. This includes not only ‘contacts’ with the Federal Government, Regions, Communities and the official authorities, but also the representation in the lap of numerous committees both at regulatory level and in terms of the health of the drug delivery control.
The APB members provide services including legal assistance, social and economic information, scientific and pharmaceutical documentation, etc.
In addition, the Office for Drug Research (DGO) part of the APB. The core of this officially recognized and accredited laboratory analysis, monitoring and systematic, periodic rechecking of medicines and products with a quality label.
Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company…
Professor Sylvie Rottey, president of the Belgian Society of Medical Oncology (BSMO) outlines the state of cancer care in Belgium, the country’s positioning in clinical trials for medical oncology, and…
Erik Present is president of Healixia, a newly formed association for medical professionals in Belgium. Present introduces the mission and purpose of Healixia, the work it is currently undertaking in…
Sabena Solomon, general manager of GSK Benelux, speaks about her first impressions of the Belgium market, having come from GSK Finland, and her initial priorities for leading the affiliate. Solomon…
Karel Van De Sompel, country manager of Pfizer in Belgium and Luxembourg and chairman of Pharma.be, highlights the key changes he sees in today’s pharma market which revolve around the…
Professor Stéphane De Wit, head of the Department of Infectious Diseases at St Pierre University Hospital outlines Belgium’s approach to tackling HIV treatment, how academia-industry collaboration is progressing in the…
In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European…
Francis Arickx, country coordinator of Belgium for the Beneluxa Initiative, introduces the project and its mission to help shape a unified healthcare policy approach between its member countries through activities…
Ian Wilders of Spain-headquartered micro-immunotherapy specialist Labo’Life discusses the strategic importance of Belgium to the company as the country in which micro-immunotherapy was discovered and where regulation conducive to the…
Luc Van Gorp of the Christian Mutuality Health Insurance Fund, Belgium’s largest health insurance fund, explains the organisation’s role within the Belgian healthcare system, how increased consolidation in recent years…
Dirk Reyn of Flanders.bio highlights what the Flanders region has to offer the life sciences and biotech industries in terms of research infrastructure, funding opportunities, and inter-industry collaboration. In…
Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as…
See our Cookie Privacy Policy Here
